Gilead, small molecule

Gilead, Terray to collaborate on small molecule drugs
Gilead Sciences (GILD) and Terray Therapeutics have entered into a strategic collaboration to discover and develop small molecule therapeutics. Read more here.
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.
Gilead, Terray Therapeutics announce research collaboration
Gilead (GILD) and Terray Therapeutics announced that the companies have entered into a strategic collaboration to discover and develop novel,
Gilead inks multi-target deal with Terray Therapeutics
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics.
Gilead Sciences, Terray Therapeutics Set AI-Powered Research Collaboration
Gilead Sciences is working with AI-powered biotechnology company Terray Therapeutics to use artificial intelligence to discover and develop small-molecule therapies across multiple targets. Gilead on Tuesday said Terray will use its tNova platform,
Gilead Inks Strategic Collaboration With Terray Therapeutics To Develop Small Molecule Therapies
Gilead Sciences, Inc. (GILD) and Terray Therapeutics, Inc. announced Tuesday that the companies have entered into a strategic
Gilead gets FDA breakthrough therapy status for Trodelvy
Gilead Sciences (NASDAQ:GILD) said it has received FDA Breakthrough Therapy Designation for its antibody-drug conjugate ...
FierceBiotech5h
Fresh off $120M raise, AI-powered Terray is teaming up with Gilead in multi-pronged R&D pact
Terray is ending the year on a high. Just two short months ago the biotech came out with a healthy $120 million series B ...
Gilead Sciences Inc. stock rises Monday, still underperforms market
Gilead Sciences Inc. closed $6.85 short of its 52-week high ($98.90), which the company achieved on November 11th.
BioPharma Dive20h
Padlock investors sue Bristol Myers; Dietmar Berger is Gilead’s new CMO
Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal.
STAT5d
Gilead to test once-a-year HIV prevention shot
Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.
Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...
Zacks.com on MSN1d
Gilead (GILD) Upgraded to Buy: Here's Why
Gilead Sciences (GILD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- ...